Plasma levels of microRNA-24, microRNA-320a, and microRNA-423-5p are potential biomarkers for colorectal carcinoma

Abstract

BackgroundMicroRNAs are stable and easy to detect in plasma. The plasma levels of microRNAs are often changed in disease conditions, including cancer. This makes circulating microRNAs a novel class of biomarkers for cancer diagnosis. Analyses of online microRNA data base revealed that expression level of three microRNAs, microRNA-24 (miR-24), microRNA-320a (miR-320a), and microRNA-423-5p (miR-423-5p) were down-regulated in colorectal cancer (CRC). However, whether the plasma level of these three microRNAs can serve as biomarkers for CRC diagnosis and prognosis is not determined.MethodsPlasma samples from 223 patients with colorectal related diseases (111 cancer carcinoma, 59 adenoma, 24 colorectal polyps and 29 inflammatory bowel disease) and 130 healthy controls were collected and subjected to reverse transcription-quantitative real time PCR (RT-qPCR) analyses for the three microRNAs. In addition, plasma samples from 43 patients were collected before and after surgical treatment for the same RT-qPCR analyses.ResultsThe concentrations of plasma miR-24, miR-320a and miR-423-5p were all decreased in patients with CRC and benign lesions (polyps and adenoma) compared with healthy controls, but increased in inflammatory bowel disease (IBD). The sensitivity of miR-24, miR-320a and miR-423-5p for early stage of CRC were 77.78 %, 90.74 %, and 88.89 %, respectively. Moreover, the plasma concentration of the three microRNAs was increased in patients after the surgery who had clinical improvement.ConclusionsThe plasma levels of miR-24, miR-320a, and miR-423-5p have promising potential to serve as novel biomarkers for CRC detection, especially for early stage of CRC, which are superior to the currently used clinical biomarkers for CRC detection, such as CEA and CA19-9. Further efforts to develop the three microRNAs as biomarkers for early CRC diagnosis and prediction of surgical treatment outcomes are warrant.Electronic supplementary materialThe online version of this article (doi:10.1186/s13046-015-0198-6) contains supplementary material, which is available to authorized users.

Retracted - miR-423-5p knockdown enhances the sensitivity of glioma stem cells to apigenin through the mitochondrial pathway

“…Fang et al 24 found that miR-423-5p is downregulated in the plasma of colorectal cancer (CRC) cells and that it could serve as a potential biomarker for colorectal carcinoma. Stiuso et al 25 showed that miR-423-5p promotes autophagy in hepatocarcinoma cells, and miR-423-5p was also found to regulate cell proliferation and invasion in gastric cancer cells.…”

miR-423-5p contributes to a malignant phenotype and temozolomide chemoresistance in glioblastomas

“…22,23 Several studies have reported that miR-423-5p functions as a biomarker and has important roles in many types of cancers. [24][25][26] However, there is no research to date that refers to the role of miR-423-5p in glioma tissues. In this study, we report that miR-423-5p is overexpressed in GBMs and is a novel tumor promoter in GBM.…”

Circulating MicroRNAs in Colorectal Cancer

“…As a result, circulating miRNAs aim to screen for the detection of CRC should have an efficiency at delineating the earlier lesions. Combined the above miRNAs, a unique serum or plasma expression profile of miR-15b, miR-17, miR-18a, miR-21, miR-23a-3p, miR-24, miR-142-3p, miR-142-5p, miR-195, miR-320a, miR-331, miR376c-3p, miR-423-5p, miR-532, miR-532-3p, miR-652 and miR-1290 could distinguish benign colorectal polyp or adenoma lesions from healthy controls with good accuracy or high AUC values [27][28][29][30][31][32][33]. High levels of circulating miR-34a, miR-152 and low miR-150 levels were associated with the distinguish of patients with polyps or adenomas from those with CRC (AUC from 0.537 to 0.904) [34].…”